SynthesisCurrent oncology (Toronto, Ont.)2026
Predictors and Risk Assessment Models for Venous Thromboembolism in Patients Diagnosed with Lymphoma: A Systematic Review.
Synthesis in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among hematological malignancies, lymphoma is associated with an increased incidence of venous thromboembolism (VTE) ranging between 4 and 12%. Although Khorana score was validated for stratifying VTE risk in cancer, its discrimination reliability in lymphoma is reduced by the lack of specific predictors. The aim of this systematic review was to summarize the evidence regarding predictors and available risk assessment models (RAMs) for VTE in patients with lymphoma. A systematic search was conducted on PubMed, Embase and Scopus in order to identify papers published until February 2026, which evaluated predictors and RAMs for VTE in patients diagnosed with lymphoma. Out of 592 evaluated papers, 44 met the inclusion criteria. The widely used Khorana score failed to appropriately identify patients with lymphoma at high risk for VTE, while the Thrombosis Lymphoma predictive score (ThroLy) showed modest improvement. Strong predictors for VTE were a poor performance status, older age, previous history of VTE, the use of central venous catheters, and bulky disease. However, the lack of external validation, the small sample size and bias due to confounding factors limit the generalizability of the results. Therefore, larger studies with external validation cohorts are needed to design lymphoma-specific RAMs and to identify predictors with high discrimination power.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.